BioSpace News Archive

According to Nova one advisor, the global Thrombosis Drugs market size is expected to hit around USD 51.7 billion by 2030 from valued at USD 25.9 billion in 2021 and growing at a CAGR of 11.2% from 2022 to 2030.

SHINE Technologies, a next-generation fusion technology company, and SHINE Europe announced today that the Dutch government has approved a substantial grant proposal to develop a plan to produce a variety of terbium isotopes for use in nuclear medicine.

Data scientist and statistician Katie Pollard, PhD, director of the Gladstone Institute of Data Science and Biotechnology, has been elected to the National Academy of Medicine, one of the highest honors in health and medicine.

Partnering together, KLAS Research and Bain & Company today released their 2022 Healthcare Provider IT Report, highlighting what software investments providers are prioritizing over the next year, how they’re evaluating in vendors in a post-Covid world, and the key implications for providers, software players, and investors in this new period of disruption.

Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) (“Genomma Lab” or “the Company”), today announced that it will report its Third Quarter 2022 results on Wednesday, October 26, 2022 after the Mexican Market (BMV) close.

NKGen Biotech, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Investigational New Drug (IND) clearance to commence a Phase 1, open-label, dose-escalation study of its cryopreserved “off-the-shelf” allogeneic blood-derived NK cell therapy.

Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that preclinical data for the company’s novel GeneTAC™ small molecule, DT-216, as a potential treatment for Friedreich ataxia (FA) will be presented during an oral session at the International Congress for Ataxia Research (ICAR) 2022.

CTI BioPharma Corp. announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to two new employees as equity inducement awards outside of the Company’s Amended and Restated 2017 Equity Incentive Plan and material to the employees’ acceptance of employment with the company.

Silk Road Medical, Inc., a company focused on reducing the risk of stroke and its devastating impact, announced the commencement of a proposed underwritten public offering of $100 million of shares of its common stock.

Kite, a Gilead Company (Nasdaq: GILD), today announces that the European Commission (EC) has granted approval for the use of Yescarta® (axicabtagene ciloleucel) for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) who relapse within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.